Genomic & Biopharma News

Daiichi Sankyo inks $200M licensing deal with Ultragenyx to boost gene therapy manufacturing
Daiichi Sankyo is in the midst of a companywide shift to oncology as part of its 2025 business plan, a transition that has scored at least one major approval, so far. But Daiichi is also looking to life after 2025, and gene therapy could provide a lucrative roadmap moving forward. 
Fierce Pharma, 2020-04-01 13:59:03

Virtual Hospital becomes flagship test site for COVID-19 virus
The Virtual Hospital (Advanced Centre for Clinical Simulation) of Valencia's Catholic University (UCV) has become the flagship site for the tests of researchers, universities and companies to measure the suitability of mechanical respirator prototypes created for patients affected by COVID-19.
News Medical Life Sciences, 2020-04-01 13:33:00

Electronic Sun Sentinel: Gene analysis lab moves to Deerfield Beach

ORB Company News, 2016-12-02 21:24:27

Electronic Sun Sentinel: Gene analysis lab moves to Deerfield Beach

ORB Company News, 2016-12-02 21:24:27

#FierceMadness: Pfizer's Talzenna, J&J's Spravato hang on for Elite Eight berths
Moving into the Final Four of the #FierceMadness drug name tournament, contenders from both Big Pharma and smaller companies remain evenly in play. AbbVie's Skyrizi and Amgen's Evenity made it through the Elite Eight, but so did Alexion's Ultomiris and Vertex's Trikafta. 
Fierce Pharma, 2020-04-01 13:32:25

As U.K.'s coronavirus toll surges, Gilead kickstarts remdesivir trials across the country
With Prime Minister Boris Johnson infected and isolated in Downing Street, and other top officials similarly afflicted with COVID-19, the U.K. is joining in the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir. The trial news comes as case counts surge and officials hustle to get hospitals ready for a surge in patients.
Fierce Biotech, 2020-04-01 12:55:11

FDA creates program to speed up coronavirus therapies
The FDA has created an emergency program to accelerate the development of treatments for the novel coronavirus. By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.
Fierce Biotech, 2020-04-01 12:23:50

Vitamin versus tumor: How niacin might help fight glioblastoma
Glioblastomas are hard to treat in part because the brain’s immune cells are suppressed and unable to launch an attack against tumors. A research team at the University of Calgary in Canada found that niacin, also known as vitamin B3, can stimulate immune cells that are otherwise compromised by brain tumors.
Fierce Biotech, 2020-04-01 12:04:26

With coronavirus rare in rural Florida, experts dispute way forward
Florida Gov. Ron DeSantis has refused to issue a statewide "stay-at-home" order to stem the spread of the novel coronavirus because the disease has not hit many areas of the state, he said.
News Medical Life Sciences, 2020-04-01 11:59:18

Physical activity beneficial for mental well-being in middle-aged women despite menopausal status
A recent study has found that late menopausal status is associated with an elevated level of depressive symptoms that indicate the negative dimension of mental well-being.
News Medical Life Sciences, 2020-04-01 11:55:16

Brii, Chinese partners eye Q3 start for COVID-19 antibody trial
Brii Biosciences has teamed up with a Chinese hospital and university to develop antibodies against COVID-19. The partners leveraged their proximity to the initial outbreak and experience with SARS and MERS to build up a library of potentially neutralizing antibodies, putting them on track to start testing candidates in humans in the third quarter.
Fierce Biotech, 2020-04-01 11:45:33